Biophan signs letter of intent for MRI-enabled stent technology:
This article was originally published in Clinica
Biophan has signed a letter of intent with two German biomedical researchers for a worldwide exclusive licence to a cardiovascular stent technology that enables MRI angiography of the interior of vascular stents. Developed by Drs Arno Bucker and Alexander Ruebben through the University of Aachen, the alloy metal-based technology adds to Biophan's current portfolio of resonant circuit technologies for making stents MRI-visible. The Rochester, New York firm said that conventional metallic stents prevent the use of MRI angiography due the "Faraday cage effect" - a process whereby electric charge sits on the outer surface of a conductor. The company also has the option to sub-license the technology to third parties.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.